Skip to main content
TipRanks
Go Ultimate75% OFF

TherapeuticsMD (TXMD) AI Stock Analysis

2,250 Followers
TXMD

TherapeuticsMD

(NASDAQ:TXMD)

Select Model
Rating:47Neutral
Price Target:$2.00â–²(6.95% Upside)
Action:reiterated
Date:11/14/26

TXMD scores in the lower-middle range, held back primarily by a very small and shrinking operating business: trailing revenue of $2.5 million is down 24% year over year and the company still runs an operating loss, leaving earnings quality and visibility low. Valuation compounds the caution, with a P/E near 231 that reflects negligible earnings and no dividend. Technically, the stock trades below its 50-, 100-, and 200-day moving averages with a negative MACD, signalling a persistent downtrend. Partially offsetting these risks is a genuinely repaired financial structure - debt down to $4.2 million, positive equity of $27.6 million, $10.4 million of cash, and $3.4 million of free cash flow - alongside an encouraging third-quarter report showing higher net income and 60.6% license revenue growth. Overall, a de-risked but strategically uncertain micro-cap whose future hinges on how it deploys its cash and royalty streams.

Positive Factors
Improving balance sheetFalling debt and modest leverage provide greater financial flexibility and a meaningful balance-sheet cushion. Positive, stable equity further reduces solvency pressure, allowing the company to preserve resources while its royalty portfolio develops over the next several quarters.
Negative Factors
Revenue contractionA sharp TTM revenue decline weakens the base from which royalties and other operating income can grow. Continued contraction would reduce the company’s ability to absorb fixed expenses, fund initiatives internally, and convert its portfolio into consistent long-term earnings.

TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%TXMD+21.43%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$21.64M
Dividend Yield
―
Average Volume (3M)
24.41K
Price to Earnings (P/E)
230.9
Beta (1Y)
1.17
Revenue Growth
33.94%
EPS Growth
-59.77%
Country
US
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

TherapeuticsMD Business Overview & Revenue Model

Company Description

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradi...

How the Company Makes Money

TherapeuticsMD has generated revenue primarily through out-licensing/partnering arrangements for its product portfolio rather than through building a fully integrated, long-term direct commercial sales model. Under these types of agreements, the comp...

TherapeuticsMD Financial Statement Overview

Summary

A mixed picture dominated by extremely small scale. The income statement is the key weakness (score 28): trailing revenue of just $2.5 million is down roughly 24% year over year, the business still posts an operating loss of about -$3.5 million, and the near-breakeven $0.1 million net income comes from items below the operating line. The balance sheet is far stronger (score 64), with debt cut to $4.2 million from nearly $198 million, equity restored to a positive $27.6 million, and a conservative debt-to-equity ratio of 0.15. Cash flow (score 61) has turned decisively positive, with $3.4 million of operating cash flow converting fully to free cash flow under the asset-light royalty model. Net: a de-risked, clean financial structure, but an operating engine that is tiny, contracting, and concentrated in a narrow royalty stream.

Income Statement

28Negative

Balance Sheet

64Positive

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue3.75M3.02M1.76M1.30M69.96M2.57M
Gross Profit3.08M3.02M1.76M1.30M68.57M1.17M
EBITDA-4.26M-3.02M-4.33M-7.60M11.86M-78.84M
Net Income122.00K-569.00K-2.18M-10.28M112.00M-172.41M
Balance Sheet
Total Assets37.93M37.66M38.82M43.31M90.46M169.47M
Cash, Cash Equivalents and Short-Term Investments10.45M7.48M5.06M4.33M38.07M64.91M
Total Debt4.21M6.10M7.17M8.01M8.76M197.69M
Total Liabilities10.31M10.78M11.45M14.02M55.31M263.09M
Stockholders Equity27.62M26.88M27.37M29.29M35.14M-93.62M
Cash Flow
Free Cash Flow3.36M2.42M732.00K0-4.43M-147.84M
Operating Cash Flow3.36M2.42M732.00K-48.14M-4.08M-147.81M
Investing Cash Flow0000223.48M-2.22M
Financing Cash Flow0003.15M-235.21M134.67M

TherapeuticsMD Technical Analysis

Technical Analysis SentimentNeutral
Last Price1.87

Price Trends

50DMA1.97Negative
100DMA2.03Negative
200DMA2.08Negative

Market Momentum

MACD-0.05Negative
RSI51.45Neutral
STOCH90.59Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Neutral. The current price of 1.87 is above the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.97, and below the 200-day MA of 2.08, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 51.45 is Neutral, neither overbought nor oversold. The STOCH value of 90.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TXMD.

TherapeuticsMD Risk Analysis

TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

TherapeuticsMD Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TXMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AYTUAYTU62Neutral$19.35M-1.30-52.89%―-13.27%27.11%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TXMDTXMD47Neutral$21.64M230.860.45%―33.94%-59.77%
RDHLRDHL42Neutral$3.33M-0.38-438.17%―――
PRPHPRPH41Neutral$88.25K-0.00-1358.66%―――

* Healthcare Sector Average

Performance Comparison

-100%-50%0%50%TXMDPRPHRDHLAYTUGELSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TXMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TXMDTherapeuticsmd Inc1.870.3523.03%
PRPHProphase Labs0.01-2.64-99.62%
RDHLRedHill Biopharma Ltd0.38-0.67-63.94%
AYTUAytu BioScience1.78-0.20-10.10%
GELSGelteq Limited0.38-0.56-59.57%

TherapeuticsMD Corporate Events

Financial Disclosures

TherapeuticsMD Reports Third-Quarter Net Income and Revenue Growth

Positive
Nov 13, 2026

TherapeuticsMD is a pharmaceutical royalty company that primarily collects royalties from licensees; it changed from a women’s healthcare company in December 2022 and no longer engages in research and development or commercial operations. On November...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026